Beta Thalassemia Treatment Market Size & Share, by Therapy (Blood Transfusion, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplant); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5273
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Beta Thalassemia Treatment Market size is estimated to surpass USD 3 billion by the end of 2036, growing at a CAGR of 8% during the forecast period i.e. 2024-2036. In the year 2022, the industry size of beta thalassemia treatment was around USD 450 Million. The growth of this market can be primarily driven by the increasing prevalence of beta thalassemia worldwide with no viable treatment options found for curing the disease. This disease is majorly caused by to mutation in the hemoglobin subunit beta gene. The number of beta thalassemia cases found is 1 in 100,000 people in the general population worldwide. 

The market for treating beta-thalassemia around the world is significantly being driven by rising healthcare spending. Thalassemia requires extensive medical management due to its complexity, which includes routine blood transfusions, iron chelation therapy, and potentially curative treatments. The cost of diagnostic procedures, therapeutic regimens, and supporting care in healthcare increases in direct proportion to the prevalence of thalassemia. In order to drive market growth and improve results for beta-thalassemia patients, healthcare providers, research organizations, and pharmaceutical businesses invest in creating novel medications, gene therapies, and additional care choices.

Beta Thalassemia Treatment Market
Get more information on this report: Request Free Sample PDF

Beta Thalassemia Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Escalating Advancement in Technology – Increasing technological advancements such as in gene therapy and CRISPR-Cas9 are expected to offer lucrative growth opportunities for the market in the upcoming times. Additionally, improvements in medical technology, such as implantable iron level monitors and portable infusion devices for chelation therapy, improve patient results and the ease of treatment. Additionally, the use of gene therapy and transplantation of stem cell procedures holds promise for beta-thalassemia cures. These developments not only enhance patient care but also open up new avenues for the study, creation, and commercialization of innovative medicines and medical equipment in the market for treating beta-thalassemia worldwide.
  • Increasing Demand for Point-of-Care Testing - The demand for point-of-care testing is expanding day-by-day, especially in developing countries as the availability of laboratory testing is limited in these regions. Therefore, there is an opportunity for market players to develop point-of-care testing items for beta-thalassemia.


  • High Cost of Beta Thalassemia Treatment - The high expense of treating beta-thalassemia presents a substantial obstacle on the international beta-thalassemia treatment market. Healthcare costs are high due to the complicated management of beta-thalassemia, which includes ongoing blood transfusions, detoxification therapy, and possibly curative treatments. Financial strains on individuals, hospitals, and payers might result from the price of specialist medications, medical support, evaluations, and lifelong maintenance. This obstacle restricts access to the best care, especially for those without access to adequate insurance and in areas with scarce healthcare resources. For patients with beta-thalassemia all over the world, it is imperative to address the high expense of therapy in order to promote fair access and enhance outcomes.
  • Lack of Viable Treatment Options for Treatment of Disease Rather than Symptoms Associated with the Disease is Expected to Hamper the Market Growth in the Upcoming Times.
  • Side Effects Associated with Treatment is Predicted to Pose Limitation on the Market Expansion in the Future.

Beta Thalassemia Treatment Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2024)

~USD 450 Million

Forecast Year Market Size (2036)

~USD 3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Beta Thalassemia Treatment Segmentation

Therapy (Blood Transfusion, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplant)

Beta thalassemia treatment market from the iron chelation therapy segment is predicted to hold the highest growth of 40% during the predicted time period. Currently, treating the symptoms of beta thalassemia is the norm rather than trying to find a solution. The majority of the treatments for the condition deal with the iron excess brought on by blood transfusions, as well as fetal hemoglobin-raising drugs, vitamin supplements, and the antioxidant indicaxanthin, which prevents hemoglobin from degrading. It is anticipated that the demand for iron-chelating therapies will present several potentials for business expansion if drugs that are presently in phase II or phase III studies are approved by the FDA.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Based on distribution channel, the hospitals pharmacies segment in the beta thalassemia treatment market is anticipated to hold a significant revenue share during the time period between 2024 - 2036. The segment is anticipated to grow as hospital pharmacies are able to offer patients access to a wide range of medications and other products as well support of healthcare professionals. Furthermore, increasing demand for innovative and effective treatments along with the development of new therapies are boosting the growth of this segment in the projected period. Reblozyl received approval from the U.S. Food and Drug Administration in November 2019 to treat anemia in adult beta-thalassemia patients who require frequent red blood cell transfusions.

Our in-depth analysis of the global beta-thalassemia treatment market includes the following segments:


  • Blood Transfusion
  • Iron Chelation Therapy
  • Folic Acid Supplements
  •  Gene Therapy
  • Bone Marrow Transplant

          Distribution Channel

  • Hospital Pharmacies
  •  Retail Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Beta Thalassemia Treatment Industry- Regional Synopsis

North America Market Forecasts

The beta thalassemia treatment market in the North America is set to hold the largest revenue share of 33% during the assessment period. The growth of the market in this region can be attributed on the account of several factors such as the increasing presence of market players in the region, and the growing research and development activities taking place for the approval and development of new technologies in beta thalassemia treatment. Bluebird Bio, a biotech company from the U.S. declared on September 21, 2021, that it had filed a formal application for approval of beticel gene therapy to treat beta-thalassemia within the United States.

APAC Market Statistics

The beta-thalassemia treatment market in the Asia Pacific region is poised to grow substantially by the end of 2036. The growth of this market can be attributed to the back of increasing investment in the healthcare infrastructure of the region, the large population patient pool, availability of massive untapped markets in the region. Besides, increasing demand for quality healthcare facilities in this region is also estimated to boost the market growth in this region in the upcoming time period.

Research Nester
Beta Thalassemia Treatment Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Beta Thalassemia Treatment Market

    • Bluebird Bio Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Acceleron Pharma, Inc.
    • Celgene Corporation
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Gamida Cell
    • Kiadis Pharma
    • La Jolla Pharmaceutical Company
    • Vertix Pharmaceuticals Incorporated
    • ApoPharma Inc.

In the News

  • Zynteglo, a new generation of gene therapy for adult and paediatric patients with beta thalassemia that requires regular red cell transfusions, has been authorised by the US Food and Drug Administration.
  • CRISPR and Vertex Pharmaceuticals Incorporated announced the Fast Track Designation for CTX001 to treat transfusiondependent beta thalassemia has been given by the United States Food and Drug Administration. CTX001 is an investigational autologous, gene edited therapy of hematopoietic stem cells for patients with severe hemoglobinopathies.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5273
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of beta thalassemia and increasing healthcare expenditure are some of the major factors anticipated to drive the growth of the cell culture consumables market.

The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2024 – 2036.

The major players in the market are of Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, Vertix Pharmaceuticals Incorporated, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Beta Thalassemia Treatment Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying